FDA Clearance Tracker · K230675
VITEK REVEAL GN AST Assay and VITEK REVEAL AST System
Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jun 20, 2024
Substantially Equivalent
Time to decision
468 days
Received Mar 10, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K230675
- Device name
- VITEK REVEAL GN AST Assay and VITEK REVEAL AST System
- Applicant
- Specific Diagnostics, LLC
- Applicant location
- San Jose, CA
- Received
- Mar 10, 2023
- Decided
- Jun 20, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Automated Antimicrobial Susceptibility Test System For Positive Blood Culture Samples (SAN)
- Device class
- Class II
- Regulation
- 21 CFR 866.1650
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SAN. The earliest in FDA's data is K211815, decided Apr 2, 2024.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for K230675
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Specific Diagnostics, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.